This is a rejoinder to the preceding commentaries on the authors' paper “Surrogate Endpoints in AIDS Drug Development: Current Status.” The authors thank Drs. Ellenberg and Gould for their thought-provoking commentaries and reiterate that information accumulation in the AIDS area, including that from meta-analyses on the concordance between CD4 count and HIV-1 RNA response with the clinical response, is dynamic and fast paced. In addition, the authors remind the readers of the calculated risk associated with decision making in the drug development process. Some information that has become available since the writing of the original manuscript is also included.
PerelsonASEssungerPCaoYDecay characteristics of HIV-1 infected compartments during combination therapy. Comments in: Nature. May 1997;387(6629):188–191.
2.
van't WoutABRanLJKuikenCLAnalysis of the temporal relationship between human immunodeficiency virus type I quasispecies in sequential blood samples and various organs obtained at autopsy. J Virol.1998;72:488–496.
3.
DeMasiRHillAMDawsonD.Meta-analysis of antiretroviral effects on HIV-1 RNA, CD4 cell count, and progression to AIDS or death. Presented at the 5th Conference on Retroviruses and Opportunistic Infections. Chicago, IL: 1998.
4.
NeselyMSuleimanJLewtDCD4 cell (CD4) and serum viral RNA (υNA) as predictors of clinical efficacy in a study of indinavir (IDV) alone and with zidovudine (ZDV) in treatment-naive HIV-1 patients with 50–250 CD4 cells/mm3. Presented at the 5th Conference on Retroviruses and Opportunistic Infections. Chicago, IL: 1998.
5.
DemeterLHughesMFischlMPredictors of virologic and clinical responses to indinavir (IDV) + ZDV + 3TC or ZDV + 3TC. Presented at the 5th Conference on Retroviruses and Opportunistic Infections. Chicago, IL: 1998.
6.
MurphyREl-SadrWCheungTImpact of protease inhibitor-containing regimens on the risk of developing opportunistic infections and mortality in the CPCRA 034/ACTG277 study. Presented at the 5th Conference on Retroviruses and Opportunistic Infections. Chicago, IL: 1998.
7.
ShaeferMShaker-IrwinLMaudeCProgression of disease in the Pacific Oaks Population Study (POPS) since the introduction of protease inhibitors and use of highly active antiretroviral therapy. Presented at the 5th Conference on Retroviruses and Opportunistic Infections. Chicago, IL: 1998.
